Authors

Latest:

Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST

The combination of bezuclastinib and sunitinib generated favorable efficacy outcomes vs historical data in patients with previously treated GIST.

Ghulam Rehman Mohyuddin, MD

Latest:

Dr. Mohyuddin on Improving Survival in Multiple Myeloma

Ghulam Rehman Mohyuddin, MD, discusses improving survival for patients with multiple myeloma.

Jason R. Westin, MD, MS, FACP

Latest:

ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma

Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.

Carlos del Rio, MD

Latest:

Dr. del Rio on Remaining Questions With the COVID-19 Vaccines

Carlos del Rio, MD, discusses remaining questions with the COVID-19 vaccines.

Alba Gonzalez-Junca, PhD

Latest:

Dr. Gonzalez-Junca on Combining IL-21 and IL-15 in NK-Cell Therapy

Alba Gonzalez-Junca, PhD, discusses combining IL-21 and IL-15 cytokines in NK-cell thearpy.

Jaffer A. Ajani, MD, MD Anderson Cancer Center

Latest:

KRAS G12C Inhibitors in mCRC

A brief discussion regarding current data and interest in treating appropriate patients with metastatic colorectal cancer with potent KRAS G12C selective inhibitors.

Ryan Nguyen, DO

Latest:

Dr. Nguyen on Enrollment Disparities in Pivotal Clinical Trials in Oncology

Ryan Nguyen, DO, discusses enrollment disparities in pivotal clinical trials in oncology.

Navneet Majhail, MD, MS

Latest:

Dr. Majhail on the Importance of Utilizing Social Media in Oncology

Navneet Majhail, MD, MS, discusses the importance of utilizing social media in oncology.

Heather A. Parsons, MD, MPH

Latest:

Dr Parsons on the Correlation Between Liquid Biopsy and HER2 Status in Breast Cancer

Heather A. Parsons, MD, MPH, discusses the correlation between liquid biopsy and HER2 status in breast cancer, according to data from a novel epigenomic platform.

Sheila Figel, PhD

Latest:

Dr. Figel on Preclinical Research With Survivin Isoforms in Cancer Cells

Sheila Figel, PhD, a neuro-oncologic scientist with Roswell Park Comprehensive Cancer Center, discusses preclinical research with canonical and noncanonical that are displayed on the surface of cancer cells.

Sponsored by BMS

Anil Vachani, MD, MS

Latest:

Novel HER2-Targeted Therapies for NSCLC

Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.

Samer Al Hadidi

Latest:

Getting the Best From Mentorship

Mentors may help in career development, personal matters, research activities, and professional growth.

Aaron Franke, MD

Latest:

Dr Franke on Treatment Options for NSCLC Expressing Uncommon EGFR Mutations

Aaron J. Franke, MD, MS, discusses treatment options for patients with uncommon EGFR mutations in non–small cell lung cancer.

Marta Vaz Batista, MD

Latest:

Dr Vaz Batista on Treating Patients With HER2+ Breast Cancer and Leptomeningeal Carcinomatosis

Marta Vaz Batista, MD, discusses the efficacy of trastuzumab deruxtecan in patients with HER2-positive or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis, as evaluated in cohort 5 of the phase 2 DEBBRAH study.

Rachel Elizabeth Rau, MD

Latest:

Blinatumomab Plus Chemo in Newly Diagnosed, Standard-Risk Pediatric B-ALL

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss data for blinatumomab plus chemotherapy in newly diagnosed pediatric ALL.

İlker Arslan, MD

Latest:

Camidge and Arslan Calculate the “Impact Factor” of a Career in Medicine

Drs Camidge and Arslan discuss Dr Arslan’s experience providing emergency medical care and the curiosity that led him to pursue a career in industry.

Juan Javier-Desloges, MD, MS

Latest:

Frontline Therapeutic Planning for Metastatic Renal Cell Carcinoma

In this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.

Azka Ali, MD

Latest:

Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer

Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.

Soo Park, MD

Latest:

Dr. Park on the Role of Cemiplimab in Advanced Basal Cell Carcinoma

Soo Park, MD, discusses the role of cemiplimab-rwlc (Libtayo) in advanced basal cell carcinoma.